Emergence Therapeutics

Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat
Problem: Solid cancers are still very difficult to treat. Most treatments increase life expectancy, but only a few lead to a complete cure. Antibody drug conjugates (ADCs) have proven to be a promising therapeutic approach, but still cause significant and toxic side effects.

The solution: Emergence Therapeutics has identified several areas where ADCs can be improved. These are the antibody itself, the toxin used to kill the cancer cell, and the linker that couples the toxin to the antibody.

Technology/ IP: The antibody-related IP is in-licensed from the University of Aix-Marseille (France) and the toxin-related IP is in-licensed from Heidelberg Pharma.
The IP and all results generated for the ADC in development will be out-licensed or sold by Emergence.

Press releases

Press
7. December 2021

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

Series A round led by Pontifax and includes new and existing investorsLead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicityStrategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021 - Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million series A financing round. T
 
Press
25. November 2020

Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing

Financing enables company to embark on additional targets and expand ADC technology reach Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of leading European investors comprising Bpifrance through its InnoBio 2 fund, Gründerfonds Ruhr, Heidelberg Pharma Research GmbH, High-Tech Gründerf
 

Info & Contact

Web:
emergencetx.com

Address

Schifferstraße 122
47059 Duisburg
Deutschland

In portfolio

26. Nov 2019

HTGF Manager

 
Dr. Anke Caßing, Principal / Authorized Signatory